JP4773512B2 - 人参サポニンＲｇ２の抽出方法及びその抽出物を含む医薬組成物とその用途 - Google Patents
人参サポニンＲｇ２の抽出方法及びその抽出物を含む医薬組成物とその用途 Download PDFInfo
- Publication number
- JP4773512B2 JP4773512B2 JP2008508731A JP2008508731A JP4773512B2 JP 4773512 B2 JP4773512 B2 JP 4773512B2 JP 2008508731 A JP2008508731 A JP 2008508731A JP 2008508731 A JP2008508731 A JP 2008508731A JP 4773512 B2 JP4773512 B2 JP 4773512B2
- Authority
- JP
- Japan
- Prior art keywords
- ginseng saponin
- ginseng
- alcohol
- saponin
- ginsenoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000208340 Araliaceae Species 0.000 title claims description 152
- 235000008434 ginseng Nutrition 0.000 title claims description 148
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims description 147
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims description 147
- 229930182490 saponin Natural products 0.000 title claims description 137
- 150000007949 saponins Chemical class 0.000 title claims description 137
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims description 133
- 238000000605 extraction Methods 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 39
- 235000019441 ethanol Nutrition 0.000 claims description 37
- 239000002244 precipitate Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000005185 salting out Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000013078 crystal Substances 0.000 claims description 15
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 8
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 238000011033 desalting Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims 3
- 241000168720 Panax japonicus Species 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 238000003809 water extraction Methods 0.000 claims 2
- 230000000382 dechlorinating effect Effects 0.000 claims 1
- 238000005137 deposition process Methods 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 description 126
- 206010012289 Dementia Diseases 0.000 description 28
- 230000000694 effects Effects 0.000 description 21
- 210000002569 neuron Anatomy 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 11
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 230000007087 memory ability Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 9
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 9
- 102000055102 bcl-2-Associated X Human genes 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000002858 neurotransmitter agent Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108700000707 bcl-2-Associated X Proteins 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 244000000626 Daucus carota Species 0.000 description 7
- 235000002767 Daucus carota Nutrition 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 6
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229960000715 nimodipine Drugs 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 229960002275 pentobarbital sodium Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000007590 Calpain Human genes 0.000 description 3
- 108010032088 Calpain Proteins 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- -1 Protopanaxatriol glycoside Chemical class 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940005524 anti-dementia drug Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 210000004565 granule cell Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 239000002664 nootropic agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical class CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034567 Peripheral circulatory failure Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002898 effect on depression Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000000246 fibrin derivative Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- VOJREVRIHQPQTJ-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCO VOJREVRIHQPQTJ-UHFFFAOYSA-N 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- LVTJOONKWUXEFR-UEZXSUPNSA-N protodioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O LVTJOONKWUXEFR-UEZXSUPNSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- QDQWGYLCDZBAMD-UHFFFAOYSA-N saponin C Natural products CC1C2C3CCC4C5(C)CCC(O)C(C)(COC6OC(CO)C(O)C(O)C6O)C5CCC4(C)C3(C)CCC27C8OC8C1(C)OC7=O QDQWGYLCDZBAMD-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2005/001204 WO2006115307A1 (en) | 2005-04-26 | 2005-04-26 | Method of extracting ginsengnoside rg2m, pharmaceutical composition including ginsengnoside rg2, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539225A JP2008539225A (ja) | 2008-11-13 |
| JP2008539225A5 JP2008539225A5 (enExample) | 2011-06-16 |
| JP4773512B2 true JP4773512B2 (ja) | 2011-09-14 |
Family
ID=37214911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508731A Expired - Fee Related JP4773512B2 (ja) | 2005-04-26 | 2005-04-26 | 人参サポニンＲｇ２の抽出方法及びその抽出物を含む医薬組成物とその用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7884195B2 (enExample) |
| EP (1) | EP1895966A4 (enExample) |
| JP (1) | JP4773512B2 (enExample) |
| WO (1) | WO2006115307A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100438876C (zh) | 2006-06-09 | 2008-12-03 | 上海中药创新研究中心 | 20(s)-原人参二醇在制备抗抑郁药物中的应用 |
| US9314493B2 (en) | 2007-05-28 | 2016-04-19 | Amorepacific Corporation | Method for treating vascular inflammation, improving skin beauty and improving male sexual function using ginseng berry |
| KR20080104600A (ko) * | 2007-05-28 | 2008-12-03 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및허혈성 심질환 치료용 조성물 |
| KR20080105470A (ko) * | 2007-05-31 | 2008-12-04 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 비만 예방 및 개선용 식품조성물 |
| WO2008155998A1 (ja) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | 抗不安抗うつ剤 |
| KR101614110B1 (ko) * | 2008-11-28 | 2016-04-21 | (주)아모레퍼시픽 | 동맥경화 예방 또는 치료용 조성물 |
| US20100278944A1 (en) * | 2009-05-04 | 2010-11-04 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
| US9956241B2 (en) | 2009-05-04 | 2018-05-01 | Naturex, S.A. | Application of American Ginseng to enhance neurocognitive function |
| KR101593618B1 (ko) * | 2009-05-26 | 2016-02-15 | (주)아모레퍼시픽 | 사포닌의 생체 이용률 증진 조성물 |
| CN102532234A (zh) * | 2010-12-10 | 2012-07-04 | 北京本草天源药物研究院 | 一种人参皂苷Rg1的提取纯化方法 |
| KR101451629B1 (ko) * | 2012-09-19 | 2014-10-21 | 제너럴바이오(주) | 스미자임 ＡＣ를 이용한 진세노사이드 Ｒｇ2의 제조방법 |
| EP2977051A4 (en) * | 2013-03-01 | 2016-10-05 | Kim S Korean Ginseng Co Ltd | GINSENOSIDZUSAMMENSETZUNG |
| JP6527744B2 (ja) * | 2014-04-16 | 2019-06-05 | 花王株式会社 | ニンジン抽出物の製造方法 |
| CN104483437B (zh) * | 2014-12-10 | 2016-06-15 | 常熟雷允上制药有限公司 | 一种抗肿瘤中药组合物的质量检测方法 |
| WO2017088080A1 (es) * | 2015-11-25 | 2017-06-01 | Natural Response S.A. | Método para la obtención de saponinas a partir de plantas |
| CN110974858A (zh) * | 2019-03-28 | 2020-04-10 | 泰州医药城国科化物生物医药科技有限公司 | 一种精制的西洋参总皂苷组分及纯化制备西洋参总皂苷的方法 |
| CN110025645B (zh) * | 2019-04-28 | 2021-05-04 | 云南汉德生物技术有限公司 | 一种提取西洋参总皂苷的方法 |
| CN110095551B (zh) * | 2019-06-12 | 2021-09-14 | 蚌埠医学院 | 一种人参皂苷的分离检测方法 |
| CN110585226B (zh) * | 2019-11-14 | 2020-08-11 | 江西厚朴贯众科技有限公司 | 金线莲苷在制备改善认知功能障碍的药物中的用途 |
| CN117327135A (zh) * | 2022-06-24 | 2024-01-02 | 中国中医科学院中药研究所 | 一种增加糖类及糖苷类成分浸出的方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083932A (en) * | 1997-04-18 | 2000-07-04 | Cv Technologies Inc. | Pharmaceutical compositions derived from ginseng and methods of treatment using same |
| CN1309969A (zh) * | 2000-01-31 | 2001-08-29 | 吉林省中医中药研究院 | 人参皂甙Rg2在制备治疗心、脑血管疾病药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1560202A (enExample) * | 1963-04-23 | 1969-03-21 | ||
| DE2828851A1 (de) | 1978-06-30 | 1980-01-10 | Shigeru Arichi | Neue antitumormittel |
| KR20000006625A (ko) | 1998-07-20 | 2000-02-07 | 묵인희 | 인삼추출물을 포함하는 치매 치료제 |
| JP2000191539A (ja) | 1998-12-22 | 2000-07-11 | Japan Science & Technology Corp | ジンセノサイドＲｂ１からなる脳細胞又は神経細胞保護剤 |
| WO2001015717A1 (en) * | 1999-08-30 | 2001-03-08 | Japan Science And Technology Corporation | Brain cell or nerve cell protecting agents comprising ginseng |
| KR100448667B1 (ko) | 2001-04-25 | 2004-09-13 | (주) 디지탈바이오텍 | 진세노사이드 가수분해물을 함유하는 퇴행성 뇌질환의예방 및 치료용 조성물 |
| KR100472380B1 (ko) | 2001-12-18 | 2005-03-08 | 나승열 | 인삼 진세노사이드를 함유하는 카이네이트에 의한 해마씨추체신경세포의 사멸 또는 손상의 예방 및 치료용 조성물 |
| KR100425022B1 (ko) * | 2002-01-05 | 2004-03-27 | 롯데제과주식회사 | 가공인삼 추출물 및 이를 함유하는 약제 조성물 |
| KR20040036451A (ko) * | 2002-10-26 | 2004-04-30 | 한국과학기술연구원 | 진세노사이드 Ｒｇ３ 또는 진세노사이드 Ｒｈ２를포함하는 글루타메이트 매개 신경독성 억제 조성물 |
| KR20050018226A (ko) | 2003-08-14 | 2005-02-23 | 주식회사 진생사이언스 | 진세노사이드를 함유하는 마그네슘-뉴클레오티드-작동성금속 이온통로 또는 세포내 칼슘고갈에 의해 작동되는칼슘통로 활성화 조성물 |
| CN100339085C (zh) * | 2003-09-23 | 2007-09-26 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药组合物 |
-
2005
- 2005-04-26 EP EP05738291A patent/EP1895966A4/en not_active Withdrawn
- 2005-04-26 US US11/912,804 patent/US7884195B2/en not_active Expired - Fee Related
- 2005-04-26 JP JP2008508731A patent/JP4773512B2/ja not_active Expired - Fee Related
- 2005-04-26 WO PCT/KR2005/001204 patent/WO2006115307A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083932A (en) * | 1997-04-18 | 2000-07-04 | Cv Technologies Inc. | Pharmaceutical compositions derived from ginseng and methods of treatment using same |
| CN1309969A (zh) * | 2000-01-31 | 2001-08-29 | 吉林省中医中药研究院 | 人参皂甙Rg2在制备治疗心、脑血管疾病药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006115307A1 (en) | 2006-11-02 |
| EP1895966A4 (en) | 2010-01-20 |
| US7884195B2 (en) | 2011-02-08 |
| US20080227760A1 (en) | 2008-09-18 |
| JP2008539225A (ja) | 2008-11-13 |
| EP1895966A1 (en) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4773512B2 (ja) | 人参サポニンＲｇ２の抽出方法及びその抽出物を含む医薬組成物とその用途 | |
| JP4418675B2 (ja) | 神経細胞の保護のためのウチワサボテン抽出物又はそれから分離した化合物を用いた医薬組成物 | |
| CN104547104B (zh) | 酸枣枝叶提取物及其制备方法和应用 | |
| CN105906672A (zh) | 藏红花色素类化合物及其用途 | |
| KR20090117736A (ko) | 선택적 세로토닌 재흡수 억제를 위한 조성물 및 그 제조 방법 | |
| JP2004518751A (ja) | Ｌｉａｎｇｔｏｕｊｉａｎ抽出物の製造方法、その抽出物を含有する医薬組成物及びその用途 | |
| JPH0725777A (ja) | 神経栄養因子合成促進剤 | |
| CN101273994A (zh) | 用于治疗糖尿病性视网膜病变的药物组合物及其制备方法 | |
| CN106397437B (zh) | 石松生物碱类化合物，其药物组合物及其制备方法和用途 | |
| KR101755097B1 (ko) | 알츠하이머성 치매 치료를 위한 뇌 조직 재생용 약제학적 조성물 | |
| CN108610387A (zh) | 一种具有神经细胞保护活性的四个异黄烷苷类化合物及其制备方法 | |
| KR100780056B1 (ko) | 인삼 사포닌 Rg2의 추출방법 및 그 추출물을 포함하는 의약조성물과 그 용도 | |
| CN101712670B (zh) | 一种3'8"-双芹菜素型双黄酮类化合物的制备方法及应用 | |
| BRPI0706865A2 (pt) | método para preparar extrato de shinyleaf yellowhorn e extrato de shinyleaf yellowhorn | |
| CN100378119C (zh) | 人参皂苷Rg2的制备方法，其药物组合物及在制药中的应用 | |
| CN114642707A (zh) | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 | |
| JP2001139483A (ja) | 薬用人蔘からなる脳細胞または神経細胞保護剤 | |
| US20170035823A1 (en) | Method for treating or suppressing degenerative brain diseases by chinese herbal medicine composition | |
| CN110090216B (zh) | 吲哚生物碱类化合物及其衍生物或盐在防治糖尿病肾病制品中的应用 | |
| CN102492008A (zh) | 一种含异红花素7-O-β-D-葡萄糖醛酸苷的活性提取物及其用途 | |
| KR101867238B1 (ko) | 고수 추출물을 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물 | |
| CN103788058B (zh) | 一种木脂素类化合物及其在防治阿尔茨海默症中的应用 | |
| CN116036153B (zh) | 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用 | |
| KR102647997B1 (ko) | 증숙생강 추출물 또는 이로부터 분리된 1-데하이드로-6-진저다이온을 유효성분으로 포함하는 퇴행성 관절염 예방, 개선, 또는 치료용 조성물 | |
| CN114681563B (zh) | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110315 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110420 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110524 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110623 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140701 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |